Pharmacokinetic interaction between SHR2554 and fluconazole: A single-center, open-label and one-sequence crossover phase I trial in healthy Chinese subjects

SHR2554, a highly selective oral EZH2 inhibitor, shows promise in treating hematologic malignancies. However, its metabolism via CYP3A4 raises concerns about drug-drug interactions. This study evaluates the impact of fluconazole, a moderate CYP3A4 inhibitor, on the pharmacokinetics and safety implic...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European journal of pharmaceutical sciences Ročník 212; s. 107163
Hlavní autoři:	Dai, Yuyang, Hu, Minwan, Guo, Shaojie, Wu, Feng, Han, Ying, Ni, Siyang, Li, Shaorong, Zhu, Zhenyu, Yuan, Weilan, Zhao, Xiuli
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier B.V 01.09.2025
Témata:	Adult Antifungal Agents - administration & dosage Antifungal Agents - pharmacokinetics Area Under Curve Cross-Over Studies CYP3A4 Cytochrome P-450 CYP3A - metabolism Cytochrome P-450 CYP3A Inhibitors - administration & dosage Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics Drug Interactions Drug-drug interaction East Asian People EZH2 inhibitor Female Fluconazole Fluconazole - administration & dosage Fluconazole - adverse effects Fluconazole - pharmacokinetics Fluconazole - pharmacology Healthy Volunteers Humans Male SHR2554 Young Adult SHR2554 Fluconazole Drug-drug interaction CYP3A4 EZH2 inhibitor
ISSN:	0928-0987, 1879-0720, 1879-0720
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	SHR2554, a highly selective oral EZH2 inhibitor, shows promise in treating hematologic malignancies. However, its metabolism via CYP3A4 raises concerns about drug-drug interactions. This study evaluates the impact of fluconazole, a moderate CYP3A4 inhibitor, on the pharmacokinetics and safety implications of SHR2554. We conducted a single-center, open-label, single-dose, single-sequence crossover phase I trial. 18 Chinese healthy subjects were orally administered SHR2554 100 mg on Day 1, fluconazole 400 mg on Day 4 and 200 mg QD from Days 5 to 6. SHR2554 100 mg co-administrated with fluconazole 200 mg on Day 7, and fluconazole 200 mg QD from Days 8 to 9. Pharmacokinetic parameters were compared after subjects were administered SHR2554 alone and in combination with fluconazole. Cmax, AUC0-t, and AUC0-∞ were significantly increased when SHR2554 was co-administered with fluconazole. The co-administration led to a 3.29-, 4.79-, and 4.13-fold increase in Cmax, AUC0-t, and AUC0-∞, respectively. Safety evaluations indicated that the observed treatment-emergent adverse events were mild and transient. These findings underline the necessity of caution when co-administered SHR2554 with moderate CYP3A4 inhibitors in clinical settings, providing crucial insights for optimizing future clinical trials. [Display omitted]
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0928-0987 1879-0720 1879-0720
DOI:	10.1016/j.ejps.2025.107163